CN101536996A - Composition for the transdermal delivery of fentanyl - Google Patents
Composition for the transdermal delivery of fentanyl Download PDFInfo
- Publication number
- CN101536996A CN101536996A CNA2009101325739A CN200910132573A CN101536996A CN 101536996 A CN101536996 A CN 101536996A CN A2009101325739 A CNA2009101325739 A CN A2009101325739A CN 200910132573 A CN200910132573 A CN 200910132573A CN 101536996 A CN101536996 A CN 101536996A
- Authority
- CN
- China
- Prior art keywords
- fentanyl
- copolymer
- minutes
- coating
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
This invention provided a transdermal drug delivery composition, comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.
Description
The application is that application number is 01816472.2, the applying date is dividing an application of calendar year 2001 27 days China national application of JIUYUE.
The application requires the priority of U.S. Provisional Patent Application 60/236,973 that JIUYUE in 2000 submitted on the 29th and the U.S. Provisional Patent Application of submitting to April 16 calendar year 2001 60/284,017.
Invention field
The present invention relates to contain the transdermal drug transmission compositions of fentanyl.The invention further relates to the transdermal drug transfer device that is used to transmit fentanyl and provide and continue the analgesic method to the experimenter of needs.
Background of invention
Designed the transdermal drug transfer device and be used for medicine through patient skin transmission treatment effective dose.The transdermal drug transfer device relates generally to remain to be introduced the carrier (for example liquid, gel or solid matrix, or contact adhesive) of medicine.Device known in the art comprises that the storage-type device that contains the film that the control medicine discharges to skin and its Chinese medicine are dispersed or dissolved in the device in substrate such as the contact adhesive.
Known for a long time fentanyl is very strong and effective anesthetis and analgesic.Fentanyl the most common as citrate through intravenous (IV) or through intramuscular (IM) administration to reach curative effect.The citric acid fentanyl is preferred for injection because of its water solublity.Fentanyl also can be used as transdermal patch or lozenge administration.Can be about fentanyl pharmacokinetics, purposes and dosage referring to following monograph, " Fentanyl Citrate ", AHFS 98Drug Information, editor: G.K.McEvoy, American Society of Health-Systems Pharmacists, p.1677-1683 (1998).
Onset is very fast after IV or IM administration, but the reduction of serum fentanyl concentration is also very fast, and this just requires with frequent interval administration.After the IV administration, onset in several minutes continues 30-60 minute.After intramuscular administration, onset in the time of about 10 minutes continues about 1-2 hour.For fentanyl, minimum effective pain relieving serum-concentration is 0.2-2ng/mL.
Oral absorption is poor, may be owing to high hepatic clearance ability in first pass (first-pass) metabolism.Pointed out to provide the lozenge of through mucous membrane and oral administration administration combination to can be used for treating the penetrability cancer pain, but it also have fugitive effect.
The fentanyl percutaneous dosing can overcome the shortcoming that aforementioned route of administration needs frequent drug administration.This also can be avoided crest and the trough that administration brought of beating, the feasible easier therapeutic dose of keeping, and do not cause the serious side effects of being brought by the peak value serum levels.
Referring to United States Patent (USP) 4,588,580, it provides fentanyl continuous general administration in 72 hours to fentanyl, can trade name through the description of dermal system
Buy.
As for concrete transcutaneous device, this device preferably should comprise a plurality of characteristics, and effectively the design of transdermal drug transfer device often participates in finding appropriate balance between these characteristics, because these characteristics are to repel mutually often.
Described device need provide the reactive compound of sufficient skin flow, and is excessive thereby its size does not need, and also should control transmission speed, thereby is enough to avoid excessive administration effect.
Described device need contain the reactive compound of capacity, thereby this chemical compound can not exhausted before specifying the end of administration time period.The administration time section was generally 7 days.
Described device should be designed to be difficult to unexpectedly transmit the dosage (that is, avoiding dose dumping) that is higher than desired amount.
Described device need keep reactive compound chemically stable and holding device self physically stable, thereby device still continues by such work of expecting after the permanent time.
Aspect chemosensitivity, chemical stimulation and mechanical stimulus, described device reply skin is non-stimulated, because it will be attached at engine body exterior for a long time.
For the patient, described device should be to make the people joyful or not prominent, perhaps has the visual characteristic of the treatment of helping.
Described device should be easy to make, and preferably has quite simply design.
Summary of the invention
The invention provides the compositions of transdermal delivery of fentanyl.In one aspect of the invention, described compositions comprises:
(a) copolymer, it comprises
(i) one or more A monomers, this A monomer are selected from alkyl acrylate that contains 4-12 carbon atom in alkyl and the alkyl methacrylate that contains 4-12 carbon atom in alkyl; With
The (ii) unsaturated B monomer of one or more ethylene linkages, this B monomer can with the A monomer copolymerization; With
(b) the about 30 weight % fentanyls of about 8 weight %-.
The present invention also is provided for a kind of compositions of transdermal delivery of fentanyl, and it comprises:
(a) contact adhesive;
(b) fentanyl; With
(c) transmit reinforcing aids, it is selected from methyl laurate, tetraglycol and its mixture.
The present invention also provides to mammal lasting analgesic method is provided, comprise amount by the about 5.0mg/ of about 0.5-days, transmit fentanyl by the transdermal drug transfer device to mammal, make the serum-concentration of fentanyl in the described mammal reach the about 10ng/mL of about 0.2-thus in about 14 days time period of about 4-.
Compositions of the present invention can adhere on the surface of the backing of making the transdermal drug transfer device.
Transdermal drug transfer device of the present invention can be used for inducing analgesis.
Detailed Description Of The Invention
The invention provides the compositions and the transdermal drug transfer device that contains these compositionss of transdermal delivery of fentanyl.
A transdermal drug of the present invention transmits compositions and comprises the copolymer that is formed by following monomer: (methyl) alkyl acrylate A monomer wherein contains 4-12 carbon atom in alkyl; With the unsaturated B monomer of ethylene linkage, this B monomer can with the A monomer copolymerization.
The acrylate copolymer that is suitable for described compositions preferably comprises based on all monomer gross weights in the copolymer and accounts for the about 95 weight % of about 40-, one or more A monomers of the about 70 weight % of 50-more preferably from about, this A monomer is selected from alkyl acrylate that contains 4-12 carbon atom in alkyl and the alkyl methacrylate that contains 4-12 carbon atom in alkyl.The suitable alkyl acrylate and the example of alkyl methacrylate comprise normal-butyl, n-pentyl, n-hexyl, different heptyl, n-nonyl, positive decyl, isohesyl, 2-ethyl octyl group, iso-octyl and the 2-ethyl hexyl ester of acrylic acid and methacrylic acid.Preferred alkyl acrylate comprises Isooctyl acrylate monomer, 2-ethylhexyl acrylate, n-butylacrylate and acrylic acid cyclohexyl ester.Isooctyl acrylate monomer is particularly preferred A monomer.
Acrylate copolymer also comprises based on all monomer gross weights in the copolymer and accounts for the about 55 weight % of about 5-, more preferably from about one or more B monomers of the about 45 weight % of 5-.Suitable B monomer comprises and contains the monomer that is selected from following functional group: carboxylic acid, sulfonamide, urea, carbamate, carboxylic acid amides, hydroxyl, amino, oxygen base, oxo and cyano group.The B monomer of example comprises acrylic acid, methacrylic acid, maleic acid, the acrylic acid hydroxy alkyl ester that in hydroxyalkyl, contains 2-4 carbon atom, the hydroxyalkyl methacrylate that in hydroxyalkyl, contains 2-4 carbon atom, acrylamide, Methacrylamide, the alkyl-substituted acrylamide that in alkyl, contains 1-8 carbon atom, N-vinyl-N-methylacetamide, N-vinyl valerolactam, the N-caprolactam, N-vinyl-2-Pyrrolidone, glycidyl methacrylate, vinyl acetate, the acrylic acid alcoxyl base ethyl ester that in alkoxyl, contains 1-4 carbon atom, the methacrylic acid alkoxyalkyl methacrylate that in alkoxyl, contains 1-4 carbon atom, acrylic acid 2-ethoxy ethoxy ethyl ester, acrylic acid bran ester, methacrylic acid bran ester, tetrahydrofurfuryl acrylate, tetrahydrofurfuryl methacrylate, the propylene glycol monomethyl acrylate, the expoxy propane methyl ether acrylate, acrylic acid two (rudimentary) alkyl amino ethyl ester, methacrylic acid two (rudimentary) alkyl amino ethyl ester, (two (rudimentary) alkyl amino propyl group) Methacrylamide, acrylonitrile and methacrylonitrile.Preferred B monomer comprises acrylic acid 2-hydroxyethyl ester, acrylamide and vinyl acetate.Particularly preferred B monomer is an acrylic acid 2-hydroxyethyl ester.
Described copolymer can randomly further comprise the macromonomer that is essentially linear, its can with A and B monomer copolymerization, and its weight average molecular weight is about 500,000 for about 500-, and is preferably about 2,000-is about 100,000, more preferably from about 4,000-about 20,000.In use, based on all monomer gross weights in the copolymer, described macromonomer amount is not more than about 20 weight % usually, preferably is not more than about 10 weight %.Suitable macromonomer comprises that sense stops polymethyl methacrylate, styrene/acrylonitrile, polyethers and the polystyrene macromolecular monomer of (functionally terminated).The description of available macromonomer example and its preparation method is referring to Krampe etc., United States Patent (USP) 4,693,776, and its content is incorporated herein by reference.The polymethyl methacrylate macromonomer is particularly preferred.
Above-mentioned copolymer can be by method preparation well known to those skilled in the art, the relevant description referring to United States Patent (USP) RE 24,906 (Ulrich), United States Patent (USP) 4,732,808 (Krampe), with the open WO 96/08229 (Garbe) in the world, its content is incorporated herein by reference.
When being used for compositions of the present invention or device, the intrinsic viscosity of copolymer of the present invention should finally can provide suitable contact adhesive.The intrinsic viscosity of preferred copolymer is extremely about 2.0dL/g of about 0.2dL/g, and more preferably from about 0.3dL/g is to about 1.4dL/g.
Based on the gross weight of described compositions, the amount of fentanyl in described compositions is the about 30 weight % of about 8 weight %-, about 12 weight %-24 weight %.In preferred embodiments, compositions is substantially free of or does not contain undissolved fentanyl.Can measure the existence of not dissolving fentanyl by the light microscopy that amplifies with 20x.The ability of dissolution of high-concentration fentanyl has some advantages in these compositionss, is included in the long period section, about 14 days of for example about 4-, preferred about 7 days, the ability of transmission therapeutic dose fentanyl.Transmission is enough to reach fentanyl in the compositions of required therapeutic outcome specified quantitative will according to curing the disease disease, skin surface any and that the medicine of fentanyl co-administered, desirable treatment persistent period, device are placed is long-pending and position and auxiliary agent and percutaneous transfer device in other components selection change.As needs, compositions can contain the component of improving the copolymer characteristic, and for example those skilled in the art are easy to determine the plasticizer of type and consumption and thickening agent etc.
In preferred embodiments, the present composition further contains the auxiliary agent that strengthens the transmission of fentanyl percutaneous.No matter how to reach potentiation, the auxiliary agent of any enhancing fentanyl percutaneous transmission all can be used in the present composition.
Proper auxiliary agent comprises some the pharmaceutically acceptable material that is used as dermal penetration enhancer or solubilizing agent in the transdermal drug transmission system.The material of example comprises C
8-C
36Fatty acid such as isostearic acid, sad and oleic acid; C
8-C
36Aliphatic alcohol such as oleyl alcohol and dodecanol; C
8-C
36The lower alkyl esters of fatty acid such as ethyl oleate, isopropyl myristate, butyl stearate and methyl laurate; C
6-C
8Two lower alkyl esters such as the diisopropyl adipate of diacid; C
8-C
36The mono glycerinate of fatty acid such as glyceryl monolaurate; Tetraglycol (tetrahydrofurfuryl alcohol polyglycol ether); Tetraglycol (ethanol, 2,2 '-(oxygen base two (inferior ethoxyl)) diethylene glycol); 2-pyrrolidone-5-carboxylic acid C
6-C
36Arrcostab; Polyethylene Glycol; Propylene glycol; 2-(2-ethoxy ethoxy) ethanol; The diglycol monotertiary methyl ether; N, N-dimethyl dodecane amine n-oxide; With their combination.The alkyl aryl ether of polyethylene glycol oxide, polyethylene glycol oxide monomethyl ether and polyethylene glycol oxide dimethyl ether also are suitable, and solubilizing agent also is suitable as glycerol and N-Methyl pyrrolidone.Terpenes is another kind of available softening agent, comprise pinene, d-limonene, carene, terpinol, 4-terpineol, carveol, carvone, pulegone, menthone,
Ketone,
Alcohol, new
Alcohol, thymol, Camphora, Borneolum Syntheticum, citral, ionone and eucalyptole, it uses separately or in any combination.
The preferred reinforcing aids that transmits comprises ethyl oleate, isopropyl myristate, glycerol, tetraglycol, methyl laurate, N, N-dimethyl dodecane amine n-oxide, limonene, terpinol, tetraglycol, propylene glycol and
Alcohol.Particularly preferred transmission reinforcing aids is tetraglycol and methyl laurate.
Auxiliary agent is to be dispersed in the described compositions in compositions of the present invention, preferably be evenly dispersed in the described compositions basically, more preferably be dissolved in the described compositions, when using following dermal osmosis model measurement, compare with the analogous composition that does not contain this auxiliary agent, the amount of described auxiliary agent causes the fentanyl percutaneous permeation to strengthen.The total amount of transmitting reinforcing aids is normally based on the about 40 weight % of about 5-of compositions gross weight.
The physical characteristic of wishing in the transdermal drug transfer device is well-known to those skilled in the art.For example, wish that apparatus of the present invention have enough few cold flow, thereby device is stable when storing for flowing.Also preferred its adheres to skin well and removes from skin cleanly.In order to realize anti-cold flow properties, select skin adherence and cleaning to remove amount and structure, the intrinsic viscosity of copolymer and the amount and the type of auxiliary agent of comonomer in level, the copolymer, thereby make adhesive phase reach the desirable balance of these characteristics.
The present invention also provides the contact adhesive composition that is used for transdermal delivery of fentanyl, and it comprises polymer, fentanyl and transmission reinforcing aids, and described auxiliary agent is selected from methyl laurate, tetraglycol and its mixture.
The example that is suitable for the polymer type of described contact adhesive composition comprises acrylate, natural and synthetic rubber such as polyisobutylene, polysiloxanes, polyurethane and other polymer that can be used as pressure-sensitive skin adhesive composition component known in the art.But described polymer individualism or exist with combining form.Above specifically described acrylate copolymer be the contact adhesive that is preferred for the present composition.
In this embodiment of the present invention, the amount of fentanyl in compositions is the about 30 weight % of about 1 weight %-based on the compositions gross weight, the preferred about 24 weight % of about 5 weight %-.Described compositions preferably is substantially free of or does not contain undissolved fentanyl.Can measure the existence of not dissolving fentanyl by the light microscopy that amplifies with 20x.Transmission is enough to reach fentanyl in the compositions of required therapeutic outcome specified quantitative will according to curing the disease disease, skin surface any and that the medicine of fentanyl co-administered, desirable treatment persistent period, device are placed is long-pending and position and auxiliary agent and percutaneous transfer device in other components selection change.As needs, compositions can contain the component of improving the copolymer characteristic, and for example those skilled in the art are easy to determine the plasticizer of type and consumption and thickening agent etc.
Based on the gross weight of compositions, transmit the about 40 weight % of the normally about 5-of total amount of reinforcing aids.The present invention further provides to mammal lasting analgesic method is provided, comprise amount by the about 5.0mg/ of about 0.5-days, transmit fentanyl by the transdermal drug transfer device to mammal, make the serum-concentration of fentanyl in the described mammal reach the about 10ng/mL of about 0.2-thus in about 14 days time period of about 4-.In preferred embodiments, described device transmits 0.5-2.5mg/ days fentanyls to the mammal percutaneous, makes the serum-concentration of fentanyl in the described mammal reach the about 4ng/mL of about 0.3-in about 8 days time period of about 6-thus.Preferred transdermal drug transfer device contains above-mentioned composition and is used for transdermal delivery of fentanyl.
Needing the fentanyl amount of transmitting and treating effective serum-concentration has very big-difference between individuality.Fentanyl tolerance is normally developed out with continuous use, be typically need be with treatment time the situation of increased dosage amount.Because in this patient and the difference between the patient, the effective serum-concentration of multiple treatment of fentanyl has been seen in report.Further description can be referring to monograph " Fentanyl Citrate ",
AHFS 98Drug InformationEditor: G.K.McEvoy, American Society of Health-Systems Pharmacists, p.1677-1683 (1998), " Fentanyl:A Review for Clinical and Analytical Toxicologists ", A.Poklis, Clinical Toxicology, 33 (5), 439-447 (1995).
Percutaneous transfer device of the present invention also comprises backing.Described backing is flexible, thereby makes device comply with skin.Suitable back lining materials comprises the conventional flexible back lining materials that is used for the contact adhesive band, polyethylene for example, particularly low density polyethylene (LDPE), linear low density polyethylene, metallocene polyethylene, high density polyethylene (HDPE), polypropylene, polyester such as polyethylene terephthalate, the nylon fiber of random orientation, vinyl-vinyl acetate copolymer, polyurethane, natural fiber such as rayon etc.Stratified backing also is suitable as polyethylene terephthalate-aluminum-polyethylene composite.For the component of adhesive phase, described backing should be inert basically.
Transdermal delivery device of the present invention is preferably as follows preparation: copolymer, auxiliary agent and fentanyl are combined to obtain coating composition with organic solvent (as ethyl acetate, isopropyl alcohol, methanol, acetone, 2-butanone, ethanol, toluene, alkane and its mixture).Shake or stir described mixture up to obtaining homogeneous coating composition.Use conventional coating process (for example scraper coating or extrusion die coating) that the compositions of gained is applied on the barrier liner then, thereby the coating composition of predetermined homogeneous thickness is provided.Suitable barrier liner comprises conventional barrier liner, and it comprises known sheet material such as polyester webs, polythene net, polystyrene net or with the polyethylene coated paper of suitable fluorinated polymer or the coating of silicone base coating.Utilize conventional method then, will be coated with the barrier liner drying of described compositions and be laminated on the backing.
Percutaneous transfer device of the present invention can be made into goods form such as band, paster, plate, dressing or other any forms well known by persons skilled in the art.Usually, described device is a patch form, and its size is fit to transmit through skin the fentanyl of scheduled volume.Usually, the surface area of described device is about 5cm
2-Yue 100cm
2, preferably about 10cm
2-Yue 40cm
2
Except backing layer, another preferred transdermal drug transfer device of the present invention also contains at least three different layers.Ground floor is attached to backing, and the transdermal drug of the present invention that comprises as medicament reservoir transmits compositions.The second layer comprises rate-controlling membrane, and this film is attached on the ground floor surface of the surface opposite that contacts with backing.The 3rd layer comprises contact adhesive, and this adhesive attachment is in the film surface opposite with the ground floor contact surface with described film.When using described device, described the 3rd layer of contact experimenter's skin (" skin contacting adhesive layer ").This class device is called as " membrane rate controlled device ".
Select the film of control speed, promptly for the similar device that does not have described film, the existence of film may change the dermal osmosis situation of described device in the device.Suitable film comprises continuous film and microporous membrane.Preferred film is by the ethylene that contains the about 28 weight % vinyl acetates of about 0.5-: the continuous film of vinyl acetate copolymer preparation.Most preferred film is by the ethylene that contains the about 9 weight % vinyl acetates of about 2-: the continuous film of vinyl acetate copolymer preparation.Film thickness is generally the about 100 μ m of about 25 μ m-, preferred about 50 μ m.
Because drug delivery speed by film control, therefore can be used the multiple contact adhesive with different pharmaceutical affinity in the 3rd (contact skin) layer.The contact adhesive that uses in the skin contacting adhesive layer can to transmit compositions identical or different with the transdermal drug that uses in the accumulation layer.The contact adhesive that uses in the skin contacting adhesive layer preferably comprises and is selected from following polymer: acrylate, natural rubber, synthetic rubber such as polyisobutylene, polyisoprene, styrene block copolymer and organosilicon polymer.It is identical to transmit compositions particularly preferably in the transdermal drug that uses in the contact adhesive that uses in the skin contacting adhesive layer and the accumulation layer.
Skin contacting adhesive layer can contain at first with accumulation layer in the medicine of similar concentration, perhaps this skin contacting adhesive layer can not contain medicine, because medicine will be introduced skin contacting adhesive layer from the accumulation layer diffusion in time.
In another embodiment, transdermal drug transfer device of the present invention also contains at least two different layers except backing layer.Ground floor is also referred to as accumulation layer, and it is attached to backing, and the transdermal drug of the present invention that comprises as medicament reservoir transmits compositions.The second layer is also referred to as " rate controlling layer ", and it comprises pressure sensitive adhesive layer, and this adhesive phase is attached on the ground floor surface of the surface opposite that contacts with backing.Rate controlling layer contact experimenter skin.Rate controlling layer is used to control the speed that medicine transmits to the experimenter, and is used to make described device to be attached to experimenter's skin.Therefore, form for accumulation layer is formed identical device the dermal osmosis situation of the existence of above-mentioned rate controlling layer possibility modifier in the device with respect to rate controlling layer.This control to drug delivery speed may be because the medicine affinity difference of described two different layers, and through the difference of described two different layers drug diffusion speed.The relative thickness of the difference of described two-layer Chinese medicine affinity and/or diffusion and layer makes drug delivery speed to be controlled.This system is called " adhesive rate controlled system ".
In the preferred embodiment of adhesive rate controlled system,, second (control speed) layer is compared with first (storage) layer had lower medicine affinity described two-layer the selection." lower medicine affinity " means medicine and preferentially retains in accumulation layer, thereby when system was at equilibrium, the percentage by weight of accumulation layer Chinese medicine was greater than the percentage by weight of rate controlling layer Chinese medicine.The relative thickness of the difference of described two-layer Chinese medicine affinity and layer makes drug delivery speed to be controlled.
Described rate controlling layer is different with accumulation layer on forming.Described first and second layers can contain for example dissimilar and polymer consumption, comprise the extent of reaction, crosslinked, polymer that branching is different with the copolymer sequence.The contact adhesive of rate controlling layer preferably comprises and is selected from following polymer: acrylate, natural rubber, synthetic rubber such as polyisobutylene, polyisoprene, styrene block copolymer and organosilicon polymer, wherein preferred especially polyisobutylene.
Transdermal drug of the present invention transmits compositions and can be used for inducing analgesic effect.For causing desirable analgesis, with the time that described compositions places on the skin and reservation is enough to reach or keep the expection analgesic effect.The competent time can be by those skilled in the art according to the flow that apparatus of the present invention provided and the disease selection of curing the disease.
Provide following embodiment with further elaboration the present invention, but be not that intention limits the present invention by any way.The concentration of fentanyl and auxiliary agent is expressed as the percentage by weight based on the compositions gross weight.The concentration of A monomer, B monomer and macromonomer be expressed as based on polymer synthetic in the percentage by weight of used rate of charge.
Embodiment
Vitro skin penetration testing method
Use following method of testing to obtain the dermal osmosis data that provide among the following embodiment.When estimating the percutaneous transfer device, from 2.0cm
2Backing is peeled off in removal on the paster, this paster is applied on people's corpse skin and pushes make it and the skin even contact.Gained paster/skin laminate is following placement, and wherein paster is towards last perforate across bottom, vertical proliferation pond.The assembling diffusion cell is under-filledly received fluid (0.1M phosphate buffer, pH 6.8) with 10mL warm (32 ℃), thereby is received fluid and contact skin.During except that use, cover thief hatch.
In whole experiment, keep described pond at 32 ± 2 ℃.In whole experiment, the fluid of being received stirs with magnetic stirring apparatus, obtains uniform sample and have less diffusing barrier on skin skin surface guaranteeing.Take out at interval with the fixed time and all to be received fluid, and substitute with fresh fluid immediately.The fluid that is taken out filters through 0.45 μ m filter.Use conventional high performance liquid chromatography that last 1-2mL is analyzed fentanyl (post: PhenomenexSpherex, 75x4.6mm, 3 μ m particle diameters then; Mobile phase: 400: 200: 400 methanol: acetonitrile: buffer agent.Buffer agent is an ammonium acetate solution, and it transfers to pH with acetic acid is 6.6; Flow velocity: 2mL/ branch; Detector: ultraviolet light under the 230nm; Volume injected: 10 μ L; Running time: 1.9 minutes).Calculate the cumulant of transdermal fentanyl, and with μ g/cm
2Expression.
The stability test method
Transdermal drug transfer device (20cm
2Paster) is encapsulated in (BAREX in the bag
TM/ aluminum/polyester or BAREX
TMAnd be kept under the condition of 25 ℃/60% relative humidity and 40 ℃/75% relative humidity/aluminum/paper laminate).Use following method of testing, before paster is tested its medicament contg and/or its and preserved and the probe cohesiveness after the predetermined storage life.
The medicament contg method of testing
The medicament contg data that provide among the following embodiment are to use following method of testing to obtain.Remove the liner of paster, paster is placed the 120mL jar.(v: v) oxolane (THF): the solution of methanol (MeOH) extracts backing and coating to use 75mL 75: 25.The sample jolting is spent the night.Medicine is carried out following dilution: 10mL gained solution is put into the 44mL bottle, add the other THF of 30mL: MeOH to each bottle.Then these final diluent samples are placed autosampler vial analysis.With the gas chromatogram (GC-FID) of band flame ionisation detector, use J﹠amp; W DB-5 fused silica capillary column (15mx0.53mm i.d., (5%-phenyl)-methyl polysiloxane film of 1.5 μ m), helium is made carrier.
Probe cohesiveness method of testing
The cohesiveness data that following embodiment provides are to use digital Polyken probe adhesiveness tester 80-02-01 type, and (Amityville NY) obtains for Testing Machines, Inc..Machine is provided with as follows: speed: 0.5cm/ second, the time of staying: 2 seconds; Pattern: peak.Use the rustless steel probe.Test result be between fracture probe and the test sample surface in conjunction with required power.Power is measured with " cohesiveness g ".
Vitro skin release adhesive method
The release adhesive data that provide among the following embodiment are to use following method of testing to obtain.The release adhesive property testing is based on ASTM D3330-90.This relates to constant percentage elongation tension tester peels off from substrate with 180 ° of peel angles.Employed substrate is Vitro-Skin
TMN-19 (VS), this is a kind of artificial skin succedaneum, derives from Innovative MeasurementSolutions, Inc., it is designed in order to the simulating human skin of back.
For using VS, the ASTM method of testing has been carried out the improvement of following necessity as test substrate.Before use, at (the v: v) water: adjust VS at least 16 hours at 23 ℃ in the chamber of glycerite, that contains 70: 30 to keep constant humidity.All tests are carried out with the texturing face of VS.Take out VS from adjust chamber after, use the double-sided adhesive band that VS is adhered on the backing of foam band (3M1777,40mil (1016 μ m) is thick) immediately, described foam band is adhered on the steel plate, so that stable test surfaces to be provided.Actual measurement is carried out in the controlled environment of 23 ℃ ± 2 ℃ and 50% ± 3% relative humidity.Then that 1.0cm is wide coated sheets band is applied on the VS, and with standard 2.04kg rubber rollers once by rolling.After rolling, before peeling off test, make resident 2 minutes of the wide coated sheets band of 1.0cm.
The free end of coating band is 180 ° to inflection thereby make traveling angle.Mobile detachment rate is 6 inch per minutes (15.2cm/ branches).Bonding force is reported as g/cm.When adhesive exhibits goes out cohesional failure when mobile (binding agent split), in the result, indicate.
The preparation of copolymer
The copolymer that uses among the following embodiment prepares according to universal method as described below.Bao Dao inherent viscosity makes with the following method and to measure hereinafter: the Cannon-Fenske#50 viscometer, in being controlled in 27 ℃ water-bath, use conventional method, the flowing time of measurement 10mm polymer solution (0.15g polymer/decilitre ethyl acetate).Testing procedure and instrument see for details
Textbook of Polymer Science, F.W.Billmeyer, Wiley Interscience, second edition (1971), 84 and 85 pages.
The preparation of " drying " copolymer
To barrier liner, prepared dry copolymer by scraper coating copolymer solution.The barrier liner oven dry that has been coated with is to remove the level of solvent and reduction residual monomer.Peel dry copolymer from barrier liner then, and be kept in the container until use.
Copolymer A. preparation Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3) copolymers
Be prepared as follows masterbatch: mix Isooctyl acrylate monomer (626.4g), acrylic acid 2-hydroxyethyl ester (421.2g), the polymethyl methacrylate macromonomer (ELVACITE of 32.4g
TM1010, derive from ICI Acrylics), 2,2 '-azo two (2-methylbutyronitrile) (2.16g), ethyl acetate (1555.2g) and isopropyl alcohol (64.8g).Gained solution is divided into equal part, and places 61 quart (0.95L) coral amber vial.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 57 ℃ of rotary water baths 24 hours.At 24 hours, from rotary water bath, take out bottle, Kaifeng is recombined in 1 gallon of (3.8L) glass jar.The percentage of solids of gained copolymer is 38.1%.Intrinsic viscosity is 0.88dL/g.
Copolymer B. Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/vinyl acetate/Elvacite
TMThe preparation of 1010 (62/15/20/3) copolymers
Be prepared as follows masterbatch: mix Isooctyl acrylate monomer (714.24g), acrylic acid 2-hydroxyethyl ester (172.8g), the polymethyl methacrylate macromonomer (ELVACITE of 34.56g
TM1010, derive from ICI Acrylics), vinyl acetate (230.4g), 2,2 '-azo two (2-methylbutyronitrile) (2.304g), ethyl acetate (1210.56g) and isopropyl alcohol (37.44g).Gained solution is divided into equal part, and places 61 quart (0.95L) coral amber vial.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 55 ℃ of rotary water baths 24 hours.At 24 hours, from rotary water bath, take out bottle, Kaifeng is recombined in 1 gallon of (3.8L) glass jar.The percentage of solids of gained copolymer is 40.4%.Intrinsic viscosity is 1.13dL/g.
Copolymer C. Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/Elvacite
TMThe preparation of 1010/ vinyl acetate (60/39/1/10) copolymer
Be prepared as follows solution: mix Isooctyl acrylate monomer (150.0g), acrylic acid 2-hydroxyethyl ester (97.5g), the polymethyl methacrylate macromonomer (ELVACITE of 2.5g
TM1010, derive from ICI Acrylics), 2,2 '-azo two (2-methylbutyronitrile) is (0.375g), ethyl acetate (327.98g) and isopropyl alcohol (17.26g) be in 1 quart of (0.95L) coral amber vial.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 57 ℃ of rotary water baths 24 hours.At 24 hours, from rotary water bath, take out bottle, and Kaifeng.With vinyl acetate (25.0g) and another part 2,2 '-azo two (2-methylbutyronitrile) (0.25g) adds in the described bottle.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.The bottle sealing was also placed 57 ℃ of rotary water baths 24 hours again.At 24 hours, from rotary water bath, take out bottle, and Kaifeng.The gained copolymer is diluted to 32.7% solid with ethyl acetate (115.90g) and isopropyl alcohol (9.40g).Intrinsic viscosity is 0.98dL/g.
Copolymer D. Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/Elvacite
TMThe preparation of 1010 vinyl acetates (58.5/39/2.5/10) copolymer
Be prepared as follows solution: mix Isooctyl acrylate monomer (146.25g), acrylic acid 2-hydroxyethyl ester (97.5g), the polymethyl methacrylate macromonomer (ELVACITE of 6.25g
TM1010, derive from ICI Acrylics), 2,2 '-azo two (2-methylbutyronitrile) is (0.375g), ethyl acetate (356.25g) and isopropyl alcohol (18.75g) be in 1 quart of (0.95L) coral amber vial.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 57 ℃ of rotary water baths 24 hours.At 24 hours, from rotary water bath, take out bottle, and Kaifeng.With vinyl acetate (25.0g) and another part 2,2 '-azo two (2-methylbutyronitrile) (0.25g) adds in the bottle.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.The bottle sealing was also placed 57 ℃ of rotary water baths 24 hours again.At 24 hours, from rotary water bath, take out bottle, and Kaifeng.The percentage of solids of gained copolymer is 39.6%.Intrinsic viscosity is 0.85dL/g.
Copolymer E. Isooctyl acrylate monomer/acrylate 2-hydroxyethyl ester/Elvacite
TMThe preparation of 1010/ vinyl acetate (57/39/4/10) copolymer
Be prepared as follows solution: mix Isooctyl acrylate monomer (142.5g), acrylic acid 2-hydroxyethyl ester (97.5g), the polymethyl methacrylate macromonomer (ELVACITE of 10.0g
TM1010, derive from ICI Acrylics), 2,2 '-azo two (2-methylbutyronitrile) is (0.375g), ethyl acetate (327.98g) and isopropyl alcohol (17.25g) be in 1 quart of (0.95L) coral amber vial.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 57 ℃ of rotary water baths 24 hours.At 24 hours, from rotary water bath, take out bottle, and Kaifeng.With vinyl acetate (25.0g) and another part 2,2 '-azo two (2-methylbutyronitrile) (0.25g) adds in the bottle.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.The bottle sealing was also placed 57 ℃ of rotary water baths 24 hours again.At 24 hours, from rotary water bath, take out bottle, and Kaifeng.The gained copolymer is diluted to 34.4% solid with ethyl acetate (113.10g) and isopropyl alcohol (5.95g).Intrinsic viscosity is 0.61dL/g.
Copolymer F. Isooctyl acrylate monomer/acrylate 2-hydroxyethyl ester/Elvacite
TMThe preparation of 1010/ vinyl acetate (57/39/4/10) copolymer
Be prepared as follows masterbatch: mix Isooctyl acrylate monomer (641.25g), acrylic acid 2-hydroxyethyl ester (438.75g), the polymethyl methacrylate macromonomer (ELVACITE of 45.0g
TM1010, derive from ICI Acrylics), 2,2 '-azo two (2-methylbutyronitrile) (1.6875g), ethyl acetate (1360.215g) and isopropyl alcohol (71.590g).A part (568.55g) gained solution is placed 1 quart of (0.95L) coral amber vial.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 55 ℃ of rotary water baths 16 hours.Then the rotary water bath temperature is risen to 57 ℃, 8 hours again.At 24 hours, from rotary water bath, take out bottle, and Kaifeng.Vinyl acetate (25.0g) and other portion 2,2 '-azo two (2-methylbutyronitrile) (0.25g) adds in the bottle.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 57 ℃ of rotary water baths 24 hours again.The percentage of solids of gained copolymer is 43.9%.Intrinsic viscosity is 0.76dL/g.
Copolymer G. Isooctyl acrylate monomer/vinyl acetate/Elvacite
TMThe preparation of 1010 (56/38/6) copolymers
Be prepared as follows masterbatch: mix Isooctyl acrylate monomer (574.56g), vinyl acetate (389.88g), the polymethyl methacrylate macromonomer (ELVACITE of 61.56g
TM1010, derive from ICI Acrylics), 2,2 '-azo two (2-methylbutyronitrile) is (2.0525g) and ethyl acetate (1674.0g).Gained solution is divided into equal part, and places 61 quart (0.95L) coral amber vial.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 57 ℃ of rotary water baths 24 hours.At 24 hours, from rotary water bath, take out bottle, Kaifeng is recombined in 1 gallon of (3.8L) glass jar.The percentage of solids of gained copolymer is 27.6%.Intrinsic viscosity is 0.80dL/g.
The preparation of copolymer H. Isooctyl acrylate monomer/acrylamide/vinyl acetate (75/5/20) copolymer
Be prepared as follows masterbatch: mix Isooctyl acrylate monomer (621.0g), acrylamide (41.4g), vinyl acetate (165.6g), 2,2 '-azo two (2, the 4-methyl pentane nitrile) (1.656g), ethyl acetate (884.5g) and methanol (87.48g).A part (400g) gained solution is placed 1 quart of (0.95L) coral amber vial.To the through-flow speed of bottle is the nitrogen that divides of 1L/ 2 minutes.With bottle sealing and placed 45 ℃ of rotary water baths 24 hours.The gained copolymer is diluted to 30.5% solid with ethyl acetate (183.6g) and methanol (20.4g).Intrinsic viscosity is 1.39dL/g.
Embodiment 1
Fentanyl (1.4014g) is added methanol (6.0056g), mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 8.6788g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A) and ethyl acetate (24.0541g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃), 185 (85 ℃) oven dry 2 minutes, 225 (107 ℃) oven dry 2 minutes.The gained coating contains 13.9% fentanyl.The laying that has been coated with is pressed onto backing (SCOTCHPAK
TM1012 polyester film laminates; Derive from 3M company).Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 1 below.Use above-mentioned method of testing to determine the stability test result of fentanyl content and probe adhesion strength.The result is as shown in table 2 below.
Embodiment 2
Fentanyl (0.5589g) is added methanol (3.0770g), mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 2.9409g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A), methyl laurate (1.5602g) and ethyl acetate (12.0039g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃), 185 (85 ℃) oven dry 2 minutes, 225 (107 ℃) oven dry 2 minutes.The gained coating contains 11.0% fentanyl and 30.8% methyl laurate.The laying that has been coated with is pressed onto backing (SCOTCHPAK
TM1012 polyester film laminates; Derive from 3M company).Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 1 below.
Embodiment 3
Fentanyl (0.4964g) is added in the methanol (3.00468g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 3.0096g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A), isopropyl myristate (1.5094g) and ethyl acetate (12.0550g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃), 185 (85 ℃) oven dry 2 minutes, 225 (107 ℃) oven dry 2 minutes.The gained coating contains 9.9% fentanyl and 30.1% isopropyl myristate.The laying that has been coated with is pressed onto backing (SCOTCHPAK
TM1012 polyester film laminates; Derive from 3M company).Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 1 below.
Embodiment 4
Fentanyl (1.4010g) adds in the methanol (6.0567g), and mixes until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 8.5966g/acrylic acid 2-hydroxyethyl ester/vinyl acetate/Elvacite
TM1010 (62/15/20/3), from top copolymer B) and ethyl acetate (24.0166g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃), 185 (85 ℃) oven dry 2 minutes, 225 (107 ℃) oven dry 2 minutes.Then it is laminated to backing (SCOTCHPAK
TM1012 polyester film laminates; Derive from 3M company) on.The gained coating contains 14.0% fentanyl.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 1 below.Use above-mentioned method of testing to determine the stability test result of fentanyl content and probe adhesion strength.The result is as shown in table 2 below.
Embodiment 5
Fentanyl (0.5580g) is added in the methanol (3.0036g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 2.9409g/acrylic acid 2-hydroxyethyl ester/vinyl acetate/Elvacite
TM1010 (62/15/20/3), from top copolymer B), methyl laurate (1.5020g) and ethyl acetate (12.8355g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃), 185 (85 ℃) oven dry 2 minutes, 225 (107 ℃) oven dry 2 minutes.Then it is laminated to backing (SCOTCHPAK
TM1012 polyester film laminates; Derive from 3M company) on.The gained coating contains 11.2% fentanyl and 30.0% methyl laurate.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 1 below.
Embodiment 6
Fentanyl (0.4950g) is added in the methanol (3.0217g), mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 3.0268g/acrylic acid 2-hydroxyethyl ester/vinyl acetate/Elvacite
TM1010 (62/15/20/3), from top copolymer B), isopropyl myristate (1.5009g) and ethyl acetate (12.1759g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃), 185 (85 ℃) oven dry 2 minutes, 225 (107 ℃) oven dry 2 minutes.Then it is laminated to backing (SCOTCHPAK
TM1012 polyester film laminates; Derive from 3M company) on.The gained coating contains 9.9% fentanyl and 29.9% isopropyl myristate.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 1 below.
Embodiment 7
Fentanyl (0.3508g) is added in the methanol (1.5426g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 2.1536g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A) and ethyl acetate (6.0006g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 19mil (482.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, then it is laminated to backing (SCOTCHPAK 225 (107 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company) on.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 4 below.
Embodiment 8
Fentanyl (0.3382g) is added methanol (1.5075g), mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 1.7869g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A), limonene (0.3737g) and ethyl acetate (5.9952g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 19mil (482.6 μ m) is applied on the barrier liner (barrier liner of Daubert164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, then it is laminated to backing (SCOTCHPAK 225 (107 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company) on.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 4 below.
Embodiment 9-15
Use the universal method of embodiment 8, prepared a series of percutaneous transfer devices, wherein the amount of the amount of fentanyl and auxiliary agent and selection change to some extent.In all cases, employed copolymer is Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A.The character of the percentage by weight of fentanyl, the percentage by weight of auxiliary agent and auxiliary agent provides in following table 3.The surplus that reaches 100 weight % in each preparation is a copolymer.Abbreviation LI, MLA, PG and the other Biao Shi of ML Fen limonene, methyl lactate, propylene glycol and methyl laurate.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 4 below.
Embodiment 16
Fentanyl (0.2987g) is added in the methanol (1.5008g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 1.8276g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A), Polyethylene Glycol (0.4849g) and ethyl acetate (6.0052g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 20mil (508.0 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, then it is laminated to backing (SCOTCHPAK 225 (107 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company) on.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 6 below.
Embodiment 17-21
Use the universal method of embodiment 16, prepared a series of percutaneous transfer devices, wherein the amount of the amount of fentanyl and auxiliary agent and selection change to some extent.In all cases, employed copolymer is Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A.The character of the percentage by weight of fentanyl, the percentage by weight of auxiliary agent and auxiliary agent provides in following table 5.The surplus that reaches 100 weight % in each preparation is a copolymer.Abbreviation PEG, TG and TEG represent respectively PEG400 (
PEG 400), tetraglycol and tetraglycol.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 6 below.
Embodiment 22
Fentanyl (0.2985g) is added in the methanol (1.4947g), and mix until all fentanyl dissolvings.In this solution, add the exsiccant copolymer (Isooctyl acrylate monomer of 1.8214g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A),
Alcohol (0.4046g) and ethyl acetate (6.0041g) are mixed until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 10 minutes at 110 °F (43 ℃), then it is laminated to backing (SCOTCHPAK
TM9732 polyester film laminates; Derive from 3M company) on.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as above shown in the table 6.
Embodiment 23-25
Use the universal method of embodiment 22, prepared a series of percutaneous transfer devices, wherein the amount of the amount of fentanyl and auxiliary agent and selection change to some extent.In all cases, employed copolymer is Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A.The character of the percentage by weight of fentanyl, the percentage by weight of auxiliary agent and auxiliary agent provides in last table 5.The surplus that reaches 100 weight % in each preparation is a copolymer.Abbreviation MTH and TP represent respectively
Pure and mild terpinol.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as above shown in the table 6.
Embodiment 26-30
Use the universal method of embodiment 16, prepared a series of percutaneous transfer devices, wherein the amount of the amount of fentanyl and auxiliary agent and selection change to some extent.In all cases, employed copolymer is Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010 (58/39/3), from top copolymer A.The character of the percentage by weight of fentanyl, the percentage by weight of auxiliary agent and auxiliary agent provides in following table 7.The surplus that reaches 100 weight % in each preparation is a copolymer.Abbreviation ML, TG and LI represent methyl laurate, tetraglycol He limonene respectively.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 8 below.
Embodiment 31
Fentanyl (0.6430g) is added in the methanol (0.8113g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 2.5525g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010/ vinyl acetate (60/39/1/10) is from top copolymer C), tetraglycol (0.8002g) and ethyl acetate (3.1933g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 11mil (279.4 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, then it is laminated to backing (SCOTCHPAK 200 (93 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company) on.Use the peel adhesion of above-mentioned test determines vitro skin.The result is as shown in table 9 below.
aCohesional failure
bSample replaces between cohesional failure (energetically) and adhesive failure (little power)
Embodiment 32-37
Use the universal method of embodiment 31, prepared a series of percutaneous transfer devices, wherein the selection of the amount of the amount of fentanyl, auxiliary agent, auxiliary agent and Elvacite
TM1010 in copolymer content change to some extent.In all cases, employed copolymer is Isooctyl acrylate monomer/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010/ vinyl acetate.The character of the percentage by weight of fentanyl, the percentage by weight of auxiliary agent, auxiliary agent, the character and the Elvacite of copolymer
TM1010 in copolymer content in last table 9, provide.The surplus that reaches 100 weight % in each preparation is a copolymer.Abbreviation ML and TG represent methyl laurate and tetraglycol respectively.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as above shown in the table 9.
Embodiment 38
Fentanyl (1.240g) is added in the methanol (2.993g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 5.271g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010/ vinyl acetate (58.5/39/2.5/10) is from top copolymer D), methyl laurate (3.506g) and ethyl acetate (12.034g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 20mil (508.0 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, then it is laminated to backing (SCOTCHPAK 200 (93 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company) on.The gained coating contains 12.4% fentanyl and 35.0% methyl laurate.
Embodiment 39
Fentanyl (2.1994g) is added in the methanol (1.9991g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 5.6518g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010/ vinyl acetate (57/39/4/10) is from top copolymer F), tetraglycol (2.0157g), N, N-dimethyl dodecane amine n-oxide (0.1490g) and ethyl acetate (8.1121g) are mixed until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 13mil (330.2 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, then it is laminated to backing (SCOTCHPAK 225 (107 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company).The gained coating contains 22.0% fentanyl, 20.0%tetraglycol and 1.5%N, N-dimethyl dodecane amine n-oxide.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 10 below.
Embodiment 40
Fentanyl (1.8001g) is added in the methanol (2.0065g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 5.5535g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010/ vinyl acetate (57/39/4/10) is from top copolymer F), methyl laurate (2.5003g), N, N-dimethyl dodecane amine n-oxide (0.1511g) and ethyl acetate (8.0175g) are mixed until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 14mil (355.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, then it is laminated to backing (SCOTCHPAK 225 (107 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company).The gained coating contains 18.0% fentanyl, 25.0% methyl laurate and 1.5%N, N-dimethyl dodecane amine n-oxide.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 10 below.
Embodiment 41
Fentanyl (3.0314g) is added in the methanol (2.9990g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 8.7452g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010/ vinyl acetate (57/39/4/10) is from top copolymer F), tetraglycol (3.0040g), N, N-dimethyl dodecane amine n-oxide (0.2250g) and ethyl acetate (12.0046g) are mixed until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 22mil (558.8 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, then it is laminated to backing (SCOTCHPAK 225 (107 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company).The gained coating contains 20.2% fentanyl, 20.0%tetraglycol and 1.5%N, N-dimethyl dodecane amine n-oxide.Remove barrier liner, the coated face that exposes is laminated on second coated face that has been coated with barrier liner.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 10 below.
Embodiment 42
Fentanyl (2.5835g) is added in the methanol (2.9991g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 8.6686g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010/ vinyl acetate (57/39/4/10) is from top copolymer F), methyl laurate (3.9490g) and ethyl acetate (12.0020g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 22mil (558.8 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃), 185 (85 ℃) oven dry 2 minutes, 225 (107 ℃) oven dry 2 minutes.Portion is laminated to backing (SCOTCHPAK
TM9732 polyester film laminates; Derive from 3M company) on.The gained coating contains 17.0% fentanyl and 26.0% methyl laurate.Remove barrier liner, the coated face that exposes is laminated on second coated face that has been coated with barrier liner.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 10 below.
Embodiment 43
Fentanyl (1.1220g) is added in the methanol (11.9975g), and mix until all fentanyl dissolvings.In this solution, add copolymer (dry Isooctyl acrylate monomer/acrylamide/vinyl acetate (75/5/20) of 12.8842g, from top copolymer H), methyl laurate (6.0222g) and ethyl acetate (48.0729g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, portion is laminated to backing (SCOTCHPAK 225 (107 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company) on.The gained coating contains 5.6% fentanyl and 30.1% methyl laurate.Remove barrier liner, the coated face that exposes is laminated on the coated face of second coating barrier liner.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 11 below.
Embodiment 44
Fentanyl (0.5610g) is added in the methanol (5.9945g), and mix until all fentanyl dissolvings.In this solution, add copolymer (dry Isooctyl acrylate monomer/vinyl acetate/Elvacite of 6.4317g
TM1010 (56/38/6), from top copolymer G), methyl laurate (3.0226g) and ethyl acetate (24.0350g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 24mil (609.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 4 minutes at 110 °F (43 ℃),,, portion is laminated to backing (SCOTCHPAK 225 (107 ℃) oven dry 2 minutes 185 (85 ℃) oven dry 2 minutes
TM9732 polyester film laminates; Derive from 3M company) on.The gained coating contains 5.6% fentanyl and 30.2% methyl laurate.Remove barrier liner, the coated face that exposes is laminated on second coated face that has been coated with barrier liner.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 11 below.
Embodiment 45
Fentanyl (0.2732g) is added in the methanol (2.9986g), and mix until all fentanyl dissolvings.In this solution, add copolymer (dry Isooctyl acrylate monomer/acrylamide/vinyl acetate (75/5/20) of 3.3097g, from top copolymer H), methyl laurate (1.4252g) and ethyl acetate (12.0460g), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 19mil (482.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 10 minutes at 110 °F (43 ℃), portion is laminated to backing (SCOTCHPAK
TM9732 polyester film laminates; Derive from 3M company).The gained coating contains 5.5% fentanyl and 28.5% methyl laurate.Remove barrier liner, the coated face that exposes is laminated on second coated face that has been coated with barrier liner.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 12 below.
Embodiment 46
The fentanyl liquid storage is prepared as follows: fentanyl (0.7094g) is added in the methanol (1.7339g), and mix until all fentanyl dissolvings.Merge copolymer (dry Isooctyl acrylate monomer/acrylamide/vinyl acetate (75/5/20) of 3.4998g is from top copolymer H), methyl laurate (3.0293g) and ethyl acetate (12.1824g), and mix until obtaining even preparation.In this uniform coating preparation, add a fentanyl liquid storage (0.5471), mix until obtaining uniform coating formulation.The wet thickness scraper of described coating formulation with 19mil (482.6 μ m) is applied on the barrier liner (barrier liner of Daubert 164P silicone coating).Described liner through coating was dried 10 minutes at 110 °F (43 ℃), then it is laminated to backing (SCOTCHPAK
TM9732 polyester film laminates; Derive from 3M company).The gained coating contains 5.9% fentanyl and 28.3% methyl laurate.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 12 below.
Embodiment 47
Prepare the percutaneous coating according to substantially identical program with embodiment 41.The gained coating contains 20.2% fentanyl, 20.0%tetraglycol and 1.5%N, N-dimethyl dodecane amine n-oxide.Obtaining active surface area from the coating transformation is 20cm
2Transdermal patch.By everyone uses a paster with 14 human test subject of health, measure permeability through application on human skin.Carry out blood sampling with Fixed Time Interval, to determine the concentration of blood plasma fentanyl among the experimenter.The results are shown in the following table 13.
Embodiment 48
Prepare the percutaneous coating according to substantially identical program with embodiment 42.The gained coating contains 17.2% fentanyl and 25.0% methyl laurate.Obtaining active surface area from the coating transformation is 20cm
2Transdermal patch.By everyone uses a paster with 12 human test subject of health, measure permeability through application on human skin.Carry out blood sampling with Fixed Time Interval, to determine the concentration of blood plasma fentanyl among the experimenter.The results are shown in the following table 13.
Embodiment 49-54
Fentanyl (10.014g) is added in the methanol (11.64g), and mix until all fentanyl dissolvings.In this solution, add copolymer (the dry Isooctyl acrylate monomer of 33.649g/acrylic acid 2-hydroxyethyl ester/Elvacite
TM1010/ vinyl acetate (57/39/4/10) is from top copolymer E), methyl laurate (14.551g) and ethyl acetate (46.58g), mix until obtaining uniform coating formulation.Several parts of coating formulation scrapers are applied on the barrier liner (barrier liner of Daubert164P silicone coating), heavily are 10.0-12.0mg/cm to produce dry-coated material
2Accumulation layer.The laying that has been coated with is pressed onto backing (SCOTCHPAK
TM9732 polyester film laminates; Derive from 3M company).Also several parts of coating formulation scrapers being applied on the barrier liner (barrier liner of Daubert164P silicone coating), heavily is 3.0-5.0mg/cm to produce dry-coated material
2Skin contacting adhesive layer.The laying that gained has been coated with is pressed onto film (ethylene: vinyl acetate, wherein the percentage ratio of vinyl acetate changes to some extent).In each embodiment, remove liner from accumulation layer, film surface laminated that will be opposite with skin contacting adhesive layer is on accumulation layer, with the preparation membrane rate controlled device.The gained coating contains 17.2% fentanyl and 25.0% methyl laurate.Among each embodiment in accumulation layer coating weight, skin contacting adhesive layer coating weight and the film vinyl acetate percentage ratio in following table 14, provide.Use the permeability of above-mentioned test determines through people's corpse skin.The result is as shown in table 15 below.
Invention has been described with reference to some specific embodiments.Before the description that provides of mask body and embodiment be for the ease of being expressly understood the present invention, and should not be interpreted as it is the unnecessary restriction that the present invention is carried out thus.Those skilled in the art obviously understand, and can carry out multiple modification to described embodiment under the situation that does not deviate from spirit and scope of the invention.Therefore, scope of the present invention should not be limited to the clear and definite details and the structure of compositions that this description is described, and should be limited by the language of appended claims.
Claims (2)
1. the device of a transdermal delivery of fentanyl, it comprises:
(a) backing and
(b) adhere to lip-deep independent contact adhesive composition of described backing, described contact adhesive composition comprises
(i) copolymer, it comprises
(x) one or more A monomers, this A monomer be selected from moieties contain 4～about 12 carbon atoms alkyl acrylate and moieties contain 4～about 12 carbon atoms alkyl methacrylate and
(y) the unsaturated B monomer of one or more ethylene linkages, this B monomer can with the A monomer copolymerization;
(ii) based on the fentanyl of the about 8 weight % of the gross weight meter of contact adhesive composition～about 30 weight %;
Wherein said compositions does not contain undissolved fentanyl.
2. the device of claim 1, wherein said device further comprises barrier liner.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23697300P | 2000-09-29 | 2000-09-29 | |
| US60/236,973 | 2000-09-29 | ||
| US60/284,017 | 2001-04-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB018164722A Division CN100490805C (en) | 2000-09-29 | 2001-09-27 | Composition for the transdermal delivery of fentanyl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101536996A true CN101536996A (en) | 2009-09-23 |
Family
ID=41120539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009101325739A Pending CN101536996A (en) | 2000-09-29 | 2001-09-27 | Composition for the transdermal delivery of fentanyl |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101536996A (en) |
-
2001
- 2001-09-27 CN CNA2009101325739A patent/CN101536996A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100490805C (en) | Composition for the transdermal delivery of fentanyl | |
| AU2002215315A1 (en) | Composition for the transdermal delivery of fentanyl | |
| US20070148218A1 (en) | Olanzapine containing transdermal drug delivery compositions | |
| CN101536996A (en) | Composition for the transdermal delivery of fentanyl | |
| AU2007205756B2 (en) | Composition for the transdermal delivery of fentanyl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20090923 |